¼¼°èÀÇ ¼Ò¿Ü¿­´ëÁúȯ Ä¡·á ½ÃÀå
Neglected Tropical Disease Treatment
»óǰÄÚµå : 1782947
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 294 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼Ò¿Ü¿­´ëÁúȯ Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 48¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 38¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼Ò¿Ü¿­´ëÁúȯ Ä¡·á ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 3.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 48¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ NTD Ä¡·áÁ¦´Â CAGR 4.6%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 31¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. NTD ¹é½Å ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 2.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 10¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼Ò¿Ü¿­´ëÁúȯ Ä¡·á ½ÃÀåÀº 2024³â¿¡ 10¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 7.0%¸¦ ±â·ÏÇϸç 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 9¾ï 7,020¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.4%¿Í 2.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Àü ¼¼°è ¼Ò¿Ü¿­´ëÁúȯ Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

¼Ò¿Ü¿­´ëÁúȯ Ä¡·á°¡ ¼¼°è º¸°ÇÀÇ ¿ì¼±¼øÀ§°¡ µÈ ÀÌÀ¯

¼Ò¿Ü¿­´ëÁúȯ(Neglected Tropical Diseases, NTDs)Àº ÁÖ·Î Àú¼ÒµæÃþ°ú ¿­´ë Áö¿ª¿¡¼­ Àü ¼¼°è 10¾ï ¸í ÀÌ»óÀÇ »ç¶÷µé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¸®½´¸¸º´, »þ°¡½ºº´, ÁÖÇ÷ÈíÃæÁõ, µ­±â¿­À» Æ÷ÇÔÇÑ À̵é Áúº´Àº ¿ª»çÀûÀ¸·Î ´Ù¸¥ °¨¿°º´¿¡ ºñÇØ °ü½Éµµ, Àڱݵµ Á¦ÇÑÀûÀ̾ú½À´Ï´Ù. ±×·¯³ª ¼¼°èº¸°Ç±â±¸(WHO), ºô&¸á¸°´Ù °ÔÀÌÃ÷ Àç´Ü, °¢±¹ Á¤ºÎ º¸°Ç±â°ü µî Àü ¼¼°èÀûÀ¸·Î NTDs¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í¿Í ³ë·ÂÀ¸·Î NTDs Ä¡·á ¹× ÅðÄ¡ ÇÁ·Î±×·¥¿¡ ´ëÇÑ ÅõÀÚ°¡ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. NTDs°¡ °øÁߺ¸°Ç¿¡ Å« ºÎ´ãÀÌ µÈ´Ù´Â ÀνÄÀÌ È®»êµÇ¸é¼­ ÀǾàǰ À¯Åë È®´ë, ¹é½Å °³¹ß ÇÁ·Î±×·¥, º¤ÅÍ Á¦¾î Àü·«ÀÌ ½ÃÇàµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à»ç, ºñ¿µ¸®´Üü, Á¤ºÎ °£ÀÇ Çù·ÂÀ» ÅëÇØ ºñ¿ë È¿À²ÀûÀÎ Ä¡·áÁ¦ÀÇ »ý»ê°ú À¯ÅëÀ» ÃËÁøÇÏ°í °¨¿°ÀÚÀÇ Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. °øÁß º¸°Ç Á¤Ã¥ÀÌ NTD ÅðÄ¡¸¦ ÃÖ¿ì¼± °úÁ¦·Î »ïÀ¸¸é¼­ Ä¡·á ¹× ¿¹¹æ ¼Ö·ç¼Ç ½ÃÀåÀº Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

NTD Ä¡·á ¹× ¿¹¹æÀÇ ÃֽйßÀüÀº ¹«¾ùÀΰ¡?

NTD Ä¡·áÁ¦ÀÇ ¿¬±¸ °³¹ßÀº ¾à¹° Á¦Á¦, Áø´Ü µµ±¸, ¹é½Å Èĺ¸ÀÇ È¹±âÀûÀÎ ¹ßÀüÀ» °¡Á®¿Ô½À´Ï´Ù. ƯÈ÷ ¸²ÇÁ°è Çʶ󸮾ÆÁõ, Åä¾çÀü¿°¼º ±â»ýÃæÁõ°ú °°Àº Áúº´¿¡ ´ëÇÑ ´ë·® ¾à¹° Åõ¿©(MDA) ÇÁ·Î±×·¥ÀÇ Ã¤ÅÃÀº À¯ÇàÁö¿ª¿¡¼­ Áúº´ÀÇ È®»êÀ» Å©°Ô °¨¼Ò½ÃÄ×½À´Ï´Ù. º´¿ë¿ä¹ý, Àå±âÁö¼ÓÇü Á¦Á¦¸¦ Æ÷ÇÔÇÑ ½Å¾à ¹× ÀçâÃ⠾๰Àº ¾àÁ¦ ³»¼ºÀ» ÃÖ¼ÒÈ­Çϸ鼭 Ä¡·á È¿°ú¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯ÀüÇÐÀû, ºÐÀÚ»ý¹°ÇÐÀû ¿¬±¸¸¦ ÅëÇØ ¸®½´¸¸º´, µ­±â¿­ µîÀÇ Áúº´¿¡ ´ëÇÑ Â÷¼¼´ë ¹é½Å °³¹ßÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI¸¦ Ȱ¿ëÇÑ Áø´Ü ¹× ¿ø°Ý ¸ð´ÏÅ͸µ µî µðÁöÅÐ Çコ ±â¼úÀÇ ÅëÇÕÀ¸·Î Áúº´ÀÇ Á¶±â ¹ß°ß°ú Ä¡·á °èȹÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº NTD Ä¡·á ÇÁ·Î±×·¥ÀÇ È¿°ú¸¦ Çâ»ó½Ã۰í, ´õ ³ªÀº Áúº´ °ü¸®¿Í ±ÙÀýÀ» À§ÇÑ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù.

¹Î°üÇù·ÂÀº ¾î¶»°Ô ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí Àִ°¡?

NTD Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇÏ´Â µ¥ ÀÖ¾î ¹Î°ü ÆÄÆ®³Ê½ÊÀº Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, Á¦¾àȸ»ç´Â ¼¼°èº¸°Ç±â±¸¿Í Çù·ÂÇÏ¿© Àú·ÅÇÑ ÀǾàǰÀ» °³¹ß ¹× º¸±ÞÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº ±â¾÷µéÀÌ ÀǾàǰ ±âºÎ ÇÁ·Î±×·¥À» ½Ç½ÃÇØ ÇÇÇØ Áö¿ª¿¡ Àú·ÅÇÑ ºñ¿ëÀ¸·Î ¶Ç´Â ¹«·á·Î »ý¸íÀ» ±¸ÇÒ ¼ö ÀÖ´Â ÀǾàǰÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø°ú º¸Á¶±ÝÀ» ÅëÇØ »õ·Î¿î Ä¡·áÁ¦ ¿¬±¸¸¦ Àå·ÁÇϰí, ÇöÁö ÀÇ·á ÀÎÇÁ¶ó¸¦ °³¼±ÇÏ¿© Ä¡·á Á¦°øÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á ¹× ¸ð¹ÙÀÏ Çコ(mHealth) ÀÌ´Ï¼ÅÆ¼ºêÀÇ ºÎ»óÀ¸·Î ¿ø°ÝÁö¿¡¼­ÀÇ Á¶±â Áø´Ü ¹× Àû½Ã °³ÀÔÀÌ °¡´ÉÇØÁ® ÀÇ·á ¼­ºñ½º Á¦°øÀÌ ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î NTDs ÅðÄ¡¸¦ À§ÇÑ ³ë·ÂÀÌ °¡¼ÓÈ­µÇ°í ÀÖ´Â °¡¿îµ¥, ÀÌ·¯ÇÑ ÆÄÆ®³Ê½ÊÀ» ÅëÇØ Ä¡·á Á¢±Ù¼º ¹× Áúº´ °ü¸®¿¡ Å« ÁøÀüÀ» ÀÌ·ê ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

¼Ò¿Ü¿­´ëÁúȯ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼Ò¿Ü¿­´ëÁúȯ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¼¼°è º¸°Ç ÀÚ±ÝÀÇ Áõ°¡, ÀǾàǰ °³¹ßÀÇ ÁøÀü, ¹Î°ü Çù·ÂÀÇ È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Áúº´ ÅðÄ¡ ÇÁ·Î±×·¥¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¿¬±¸, Áø´Ü, ¹é½Å °³¹ß¿¡ ¸¹Àº ÅõÀÚ°¡ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ±âÈÄ º¯È­·Î ÀÎÇÑ ºÎ´ãÀÇ Áõ°¡´Â ¸Å°³Ã¼ °¨¿°ÀÇ Áö¸®Àû È®»êÀ» È®´ëÇÏ¿© È¿°úÀûÀÎ Ä¡·á ¼Ö·ç¼ÇÀÇ Çʿ伺À» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µðÁöÅÐ Çコ ±â¼ú°ú AI ±â¹Ý Áø´ÜÀÇ ÅëÇÕÀ¸·Î Àü¿°º´ ¹ß»ý Áö¿ªÀÇ Áúº´ °¨½Ã ¹× Ä¡·á Á¦°øÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü±¹¹Î ÀǷẸÇè ÃßÁø°ú Áö¿ª ÀÇ·áÁ¦µµ °­È­µµ ½ÃÀå ħÅõ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î NTDs ÅðÄ¡¸¦ À§ÇÑ ³ë·ÂÀÌ Áö¼ÓµÇ´Â °¡¿îµ¥, Çõ½ÅÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ Ä¡·á ¼Ö·ç¼Ç ½ÃÀåÀº È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, NTDs ÅðÄ¡¸¦ À§ÇØ Å« ÁøÀüÀ» ÀÌ·ê °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(NTD Ä¡·áÁ¦, NTD ¹é½Å), Áúȯ À¯Çü(µ­±â¿­ Áúȯ, ±¤°ßº´, Æ®¶óÄÚ¸¶, ºê·ê¸® ±Ë¾ç, ¿äÁ, ÇѼ¾º´, »þ°¡½ºº´, Àΰ£ ¾ÆÇÁ¸®Ä« Æ®¸®ÆÄ³ë¼Ò¸¶Áõ, ¸®½´¸¸Æí¸ðÃæÁõ, Åä¾ç Àü¿°¼º ¿¬Ã溴, ±âŸ Áúȯ À¯Çü)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Neglected Tropical Disease Treatment Market to Reach US$4.8 Billion by 2030

The global market for Neglected Tropical Disease Treatment estimated at US$3.8 Billion in the year 2024, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. NTD Drugs, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the NTD Vaccines segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 7.0% CAGR

The Neglected Tropical Disease Treatment market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$970.2 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Neglected Tropical Disease Treatment Market - Key Trends & Drivers Summarized

Why Is Neglected Tropical Disease Treatment a Growing Global Health Priority?

Neglected Tropical Diseases (NTDs) affect over one billion people worldwide, primarily in low-income and tropical regions. These diseases, including leishmaniasis, Chagas disease, schistosomiasis, and dengue, have historically received limited attention and funding compared to other infectious diseases. However, increased global awareness and the efforts of organizations such as the World Health Organization (WHO), the Bill & Melinda Gates Foundation, and various government health agencies have propelled investment into NTD treatment and eradication programs. The growing recognition of NTDs as a major public health burden has led to expanded drug distribution initiatives, vaccine development programs, and vector control strategies. Additionally, collaborations between pharmaceutical companies, non-profit organizations, and governments have facilitated the production and distribution of cost-effective treatments, improving accessibility for affected populations. As public health policies increasingly prioritize NTD eradication, the market for treatments and preventive solutions is expected to witness significant growth.

What Are the Latest Advances in NTD Treatment and Prevention?

Research and development in NTD treatment have led to groundbreaking advancements in drug formulations, diagnostic tools, and vaccine candidates. The adoption of mass drug administration (MDA) programs, particularly for diseases such as lymphatic filariasis and soil-transmitted helminthiasis, has significantly reduced disease prevalence in endemic regions. New and repurposed drugs, including combination therapies and long-acting formulations, have improved treatment efficacy while minimizing drug resistance. Additionally, genetic and molecular research has facilitated the development of next-generation vaccines for diseases like leishmaniasis and dengue. The integration of digital health technologies, including AI-driven diagnostics and remote monitoring, has also enhanced early disease detection and treatment planning. These innovations are improving the effectiveness of NTD treatment programs, paving the way for better disease control and potential eradication.

How Are Public-Private Partnerships Driving Market Expansion?

Public-private partnerships have played a crucial role in expanding access to NTD treatments, with pharmaceutical companies collaborating with global health organizations to develop and distribute affordable medications. Many firms have implemented drug donation programs, supplying life-saving treatments to affected regions at little or no cost. Additionally, government funding and grants have incentivized research into novel therapeutics, while local healthcare infrastructure improvements have facilitated treatment delivery. The rise of telemedicine and mobile health (mHealth) initiatives has further improved outreach, enabling early diagnosis and timely intervention in remote communities. As global efforts to eliminate NTDs gain momentum, these partnerships are expected to drive significant advancements in treatment accessibility and disease management.

What Are the Key Factors Driving Growth in the Neglected Tropical Disease Treatment Market?

The growth in the neglected tropical disease treatment market is driven by several factors, including increased global health funding, advancements in drug development, and expanding public-private collaborations. The growing focus on disease eradication programs has led to significant investments in research, diagnostics, and vaccine development. The rising burden of climate change, which has expanded the geographical spread of vector-borne diseases, has further intensified the need for effective treatment solutions. Additionally, the integration of digital health technologies and AI-driven diagnostics has improved disease surveillance and treatment delivery in endemic regions. The push for universal healthcare access and the strengthening of local healthcare systems have also facilitated greater market penetration. With sustained global efforts to combat NTDs, the market for innovative and cost-effective treatment solutions is expected to expand, making significant progress toward eliminating these diseases.

SCOPE OF STUDY:

The report analyzes the Neglected Tropical Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (NTD Drugs, NTD Vaccines); Disease Type (Dengue Disease, Rabies Disease, Trachoma Disease, Buruli Ulcer Disease, Yaws Disease, Leprosy Disease, Chagas Disease, Human African Trypanosomiasis Disease, Leishmaniases Disease, Soil-Transmitted Helminthiases Disease, Other Disease Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â